{"gene":"BRD4","run_date":"2026-06-09T22:02:45","timeline":{"discoveries":[{"year":2000,"finding":"BRD4 (MCAP) associates with mitotic chromosomes during cell division, remaining chromosome-bound while most nuclear regulatory factors are released into the cytoplasm. Microinjection of anti-BRD4 antibody into HeLa cell nuclei completely inhibited entry into mitosis without abrogating ongoing DNA replication, establishing a role in G2/M transition.","method":"Immunofluorescence/live-cell imaging, microinjection of neutralizing antibody, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct loss-of-function (antibody microinjection) with specific mitotic phenotype, replicated by localization experiments across multiple conditions","pmids":["10938129"],"is_preprint":false},{"year":2007,"finding":"BRD4 binds to acetylated chromatin via its double bromodomains and is found in transcription complexes including Mediator and P-TEFb elongation factor, stimulating HIV-1 transcription in a Tat-independent manner. BRD4 also serves as a cellular adaptor for papillomavirus E2 protein, tethering viral genomes to mitotic chromosomes to facilitate viral genome segregation during mitosis.","method":"Co-immunoprecipitation, transcriptional reporter assays, biochemical fractionation","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — review synthesizing multiple Co-IP and functional studies from several labs; P-TEFb and Mediator associations are well-established but this paper is a review summarizing prior experimental work","pmids":["17329240"],"is_preprint":false},{"year":2013,"finding":"A specific isoform of BRD4 functions as an endogenous inhibitor of DNA damage response signaling by recruiting the condensin II chromatin remodeling complex to acetylated histones via bromodomain interactions. Loss of this isoform results in relaxed chromatin, rapid checkpoint recovery and enhanced survival after irradiation; gain of function compacted chromatin and attenuated DNA damage signaling.","method":"High-content multiplex RNAi screen, loss-of-function and gain-of-function experiments, chromatin compaction assays, irradiation survival assays","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 / Strong — genome-wide RNAi screen with mechanistic follow-up showing direct recruitment of condensin II, complementary loss- and gain-of-function experiments with specific phenotypic readouts","pmids":["23728299"],"is_preprint":false},{"year":2015,"finding":"BRD4 can be recruited to the E3 ubiquitin ligase cereblon via a PROTAC (ARV-825), leading to ubiquitin-mediated proteasomal degradation of BRD4. BRD4 inhibition (without degradation) leads to robust BRD4 protein accumulation, whereas degradation more effectively suppresses c-MYC levels and downstream signaling.","method":"PROTAC-mediated targeted protein degradation, western blot, cell viability and apoptosis assays","journal":"Chemistry & biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — reconstitution of ubiquitin-mediated degradation using bifunctional molecule, replicated across multiple cell lines with orthogonal mechanistic readouts","pmids":["26051217"],"is_preprint":false},{"year":2016,"finding":"BRD4 and DOT1L exist in separate native protein complexes. DOT1L-mediated H3K79 dimethylation facilitates histone H4 acetylation, which in turn regulates BRD4 binding to chromatin. Genetic or pharmacological disruption of BRD4 and DOT1L showed synergistic activity against MLL leukemia, establishing a functional collaboration at highly transcribed genes near super-enhancers.","method":"Quantitative proteomics, chemoproteomics, biochemical fractionation, genetic disruption, small-molecule inhibition, ChIP-seq","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — multiple orthogonal methods (proteomics, chemoproteomics, fractionation, ChIP-seq, genetics) in a single rigorous study establishing the mechanistic relationship","pmids":["27294782"],"is_preprint":false},{"year":2016,"finding":"BRD4 interacts with the heat shock factor 1 (HSF1) and, under heat stress, is recruited to nuclear stress bodies where it regulates splicing. BRD4 depletion causes increased intron retention and reduced mRNA abundance of affected transcripts during heat stress.","method":"RNA-seq, co-immunoprecipitation, immunofluorescence, BRD4 knockdown","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP for interaction, RNA-seq for splicing phenotype, single lab with two orthogonal methods","pmids":["27536004"],"is_preprint":false},{"year":2016,"finding":"BRD4 phosphorylation by CK2 and dephosphorylation by PP2A modulates its chromatin targeting, transcription factor recruitment, and function in cancer progression. Phosphorylation status is also critical for papillomavirus E1/E2-dependent replication and viral gene transcription.","method":"Phosphorylation/dephosphorylation assays, functional transcriptional and replication assays, pharmacological modulation of CK2/PP2A","journal":"Drug discovery today. Technologies","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical assays with kinase/phosphatase, functional readouts, synthesis of multiple studies from one lab","pmids":["27769352"],"is_preprint":false},{"year":2017,"finding":"BRD4 acts as a transcriptional repressor of autophagy and lysosomal function genes via binding to the histone methyltransferase G9a/EHMT2. During starvation, AMPK and SIRT1 displace chromatin-bound BRD4 to instigate autophagy gene activation. The BRD4-NUT fusion oncoprotein also blocks autophagy and lysosome function.","method":"BRD4 knockdown, in vitro and in vivo autophagy assays, ChIP, co-immunoprecipitation, AMPK/SIRT1 pathway manipulation","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, in vitro and in vivo KD with defined autophagy phenotype, epistasis through AMPK/SIRT1 signaling cascade, replicated across multiple conditions","pmids":["28525743"],"is_preprint":false},{"year":2017,"finding":"BRD4 is required for myogenic differentiation, with preferential binding to the Myog promoter coinciding with increased H3K27 acetylation during C2C12 myoblast differentiation, whereas BRD3 downregulation enhances differentiation, establishing distinct and opposing roles for BRD4 and BRD3 in skeletal myogenesis.","method":"RNA interference knockdown of individual BET proteins, ChIP for BRD4 at Myog promoter, BET inhibitor treatment, myogenic differentiation assays","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific KD with defined differentiation phenotype plus ChIP showing promoter occupancy, single lab","pmids":["28733670"],"is_preprint":false},{"year":2018,"finding":"BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays an indispensable role in DNA replication checkpoint signaling. BRD4 inhibition causes rapid reduction in CHK1 phosphorylation and aberrant DNA replication re-initiation.","method":"Co-immunoprecipitation, BRD4 inhibition with JQ1/AZD5153, CHK1 phosphorylation assays, DNA replication assays, in vivo xenograft models","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP showing BRD4-CDC6 association plus functional DDR assays, single lab with two orthogonal methods","pmids":["29636547"],"is_preprint":false},{"year":2019,"finding":"BRD4 interacts directly with MTHFD1 (a folate pathway enzyme) in the nucleus, recruiting it to specific genomic loci. Inhibition of either BRD4 or MTHFD1 produces similar changes in nuclear metabolite composition and gene expression, establishing a direct link between folate metabolism and BRD4-dependent transcriptional regulation.","method":"Genetic and physical interaction screens, nuclear fractionation, ChIP-seq, co-immunoprecipitation, metabolomics","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — complementary genetic and physical interaction screens, nuclear fractionation, ChIP-seq, and Co-IP with functional metabolomics readout in a single study","pmids":["31133746"],"is_preprint":false},{"year":2019,"finding":"BRD4 functions as an effector of TGF-β signaling in cardiac fibroblasts, undergoing stimulus-dependent genome-wide redistribution and becoming enriched on a subset of enhancers and super-enhancers. Dynamic chromatin targeting of BRD4 is controlled in part by p38 MAPK and drives RNA polymerase II activation and fibrogenic gene expression.","method":"RNA-seq, mass spectrometry, ChIP-seq, BRD4 inhibition (JQ1), TGF-β stimulation, primary adult fibroblasts and in vivo mouse model","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (RNA-seq, mass spec, ChIP-seq) in primary cells and in vivo model, defining signal-responsive mechanism","pmids":["31409188"],"is_preprint":false},{"year":2019,"finding":"BRD4 is required for hematopoietic stem cell expansion and progenitor development in conditional knockout mice. Despite broadly occupying the macrophage genome and participating in super-enhancer formation, BRD4 is not required for macrophage super-enhancers or inflammatory LPS responses, as knockout macrophages form compensatory BRD4-less super-enhancers.","method":"Conditional knockout mice (Brd4 KO), ChIP-seq, transcriptome analysis, LPS stimulation","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo conditional KO with ChIP-seq and transcriptomics, establishing context-dependent role with epistasis in hematopoiesis vs. macrophage biology","pmids":["30842097"],"is_preprint":false},{"year":2019,"finding":"BRD4 regulates necroptosis by promoting transcription of MLKL. BRD4, IRF1, P-TEFb, and RNA polymerase II form a transcription complex at the MLKL locus, and BET inhibitors interfere with this complex formation, downregulating MLKL expression and protecting cells from necroptosis.","method":"Cell-based small-molecule screen, Co-immunoprecipitation of transcription complex components, MLKL expression analysis, necroptosis assays","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP of BRD4-IRF1-P-TEFb-RNAPII complex plus functional necroptosis phenotype, single lab","pmids":["30644439"],"is_preprint":false},{"year":2019,"finding":"BRD4 and P300 are sufficient to trigger genome-wide transcriptional competency during zygotic genome activation in zebrafish. Inhibition of histone acetylation blocks genome activation, establishing that P300 and BRD4 regulate this process through histone acetylation.","method":"Live imaging of transcription, maternal mRNA translation block, P300/BRD4 ectopic expression, histone acetylation inhibition, zebrafish embryo model","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — live-cell imaging combined with gain-of-function and loss-of-function experiments with defined molecular mechanism (histone acetylation) in an in vivo developmental system","pmids":["31211993"],"is_preprint":false},{"year":2020,"finding":"BRD4 short isoform (BRD4-S) forms nuclear condensates with liquid-like properties that colocalize with BRD4L, MED1, and H3K27ac sites. BRD4-S condensation is mediated by intrinsically disordered regions and bromodomain binding to DNA and acetylated chromatin, and BRD4-S phosphorylation diminishes condensate formation.","method":"Live-cell imaging, fluorescence recovery after photobleaching (FRAP), isoform-specific knockdown, ectopic expression, ChIP-seq, CUT&RUN","journal":"Nature structural & molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — FRAP for liquid-like properties, isoform-specific KD and OE, ChIP-seq, multiple orthogonal methods establishing phase separation mechanism","pmids":["32203489"],"is_preprint":false},{"year":2020,"finding":"BRD4 phosphorylates MYC at Thr58, leading to MYC ubiquitination and degradation. BRD4 degradation (but not inhibition) results in increased MYC protein levels. MYC inhibits BRD4's histone acetyltransferase (HAT) activity. ERK1 regulates MYC levels both directly and indirectly by inhibiting BRD4 kinase activity.","method":"In vitro kinase assay, phospho-specific antibodies, ubiquitination assays, BRD4 degradation vs. inhibition comparison, HAT activity assays","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase and HAT assays with specific mutagenesis, multiple orthogonal methods establishing BRD4 as a kinase that phosphorylates MYC at Thr58","pmids":["32482868"],"is_preprint":false},{"year":2020,"finding":"BRD4 inhibits CSF1 expression through suppressing HIF1α, thereby reducing macrophage colony-stimulating factor secretion by tumor cells and blocking proliferation of tumor-associated macrophages.","method":"BRD4 inhibitor treatment, gene expression analysis, cytokine secretion assays, xenograft and syngeneic tumor models","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological inhibition with defined molecular target (HIF1α) and functional readout in multiple cancer models, single lab","pmids":["32286255"],"is_preprint":false},{"year":2020,"finding":"BRD4 loss of function causes RNA polymerase II pausing on chromatin, leading to accumulation of R-loops (RNA:DNA hybrids) at BRD4 occupancy sites in S-phase cells, resulting in transcription-replication conflicts and DNA damage. The BRD4 C-terminal domain interacting with P-TEFb is required to prevent R-loop formation.","method":"BET protein LOF experiments, RNAPII ChIP-seq, R-loop detection (DRIP-seq), DNA damage assays, domain deletion mutants","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal genomic and biochemical methods, domain-deletion defining the CTM as necessary, mechanistically linking BRD4-PTEFb to R-loop suppression","pmids":["32966794"],"is_preprint":false},{"year":2020,"finding":"The BRD4 long isoform (BRD4-L) is tumor-suppressive while the BRD4 short isoform (BRD4-S) is oncogenic in breast cancer cell proliferation, migration, and mammary tumor formation. BRD4-S and EN1 comodulate the extracellular matrix-associated matrisome network via enhancer regulation.","method":"Isoform-specific knockdown, endogenous protein detection, transgene expression, RNA-seq, ChIP-seq, CUT&RUN, mouse tumor models","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — isoform-specific genetic perturbations in vitro and in vivo, integrated multi-omic profiling, defining opposing functional roles of the two isoforms","pmids":["32446320"],"is_preprint":false},{"year":2020,"finding":"ASXL3 directly interacts with BRD4's extra-terminal (ET) domain via a novel BRD4 binding motif (BBM), functioning as an adaptor protein that maintains BRD4 chromatin occupancy at active enhancers. Genetic depletion of ASXL3 reduces genome-wide H3K27ac levels and BRD4-dependent gene expression in SCLC.","method":"Size exclusion chromatography, mass spectrometry, western blot, Co-IP, ChIP-seq, RNA-seq, ASXL3 depletion","journal":"Genome medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple biochemical methods (SEC, MS, Co-IP) combined with ChIP-seq and RNA-seq, establishing direct protein-protein interaction and chromatin maintenance mechanism","pmids":["32669118"],"is_preprint":false},{"year":2021,"finding":"BRD4 interacts with NIPBL (a cohesin agonist) and BRD4 depletion reduces NIPBL chromatin occupancy, suggesting BRD4 stabilizes NIPBL on chromatin. BRD4 depletion compromises genome folding and loop extrusion, and individual amino acid mutations disrupting the BRD4-NIPBL interaction impede neural crest differentiation into smooth muscle.","method":"Co-immunoprecipitation, ChIP-seq, chromatin interaction mapping (Hi-C), imaging, point mutation analysis, conditional Brd4 knockout in neural crest, WAPL loss rescue experiment","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, epistasis (WAPL rescue), point mutations, and Hi-C in an in vivo neural crest model, multiple orthogonal methods establishing BRD4-NIPBL interaction in genome folding","pmids":["34611363"],"is_preprint":false},{"year":2021,"finding":"BRD4 chromatin-bound and promoter-associated forms have mutually exclusive activities: chromatin-bound BRD4 mediates histone acetyltransferase (HAT) activity for chromatin remodeling, while promoter-associated BRD4 mediates kinase activity for transcription. JNK-mediated phosphorylation at Thr1186 and Thr1212 triggers transient BRD4 release from chromatin, disrupting HAT activity and potentiating kinase activity toward RNA Pol II, PTEFb, and c-Myc.","method":"In vitro kinase and HAT activity assays, phospho-specific antibodies, JNK inhibition and stimulation, functional assays (CD8 expression, EMT)","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase and HAT assays combined with phospho-specific mutagenesis and functional readouts, establishing the JNK-BRD4 switch mechanism","pmids":["39454579"],"is_preprint":false},{"year":2021,"finding":"BRD4 is required for differentiation and maintenance of terminally fated effector CD8 T cells during infection. BRD4 binds diverse regulatory regions critical to effector T cell differentiation and controls transcriptional activity of terminal effector-specific super-enhancers in vivo. Induced deletion of Brd4 impaired terminal effector T cell phenotype maintenance.","method":"Small-molecule inhibition, RNAi, induced genetic deletion (Brd4 conditional KO), ChIP-seq, in vivo infection models, tumor microenvironment models","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple complementary loss-of-function approaches (inhibitor, RNAi, genetic deletion) with ChIP-seq, in vivo infection and tumor models","pmids":["34037670"],"is_preprint":false},{"year":2021,"finding":"BRD4 phosphorylation by CK2 modulates BRD4 dimerization. Two conserved regions, a coiled-coil motif and the BID (Basic-residue enriched Interaction Domain), form the phosphorylation-dependent dimerization domain (PDD). Bivalent inhibitors induce a conformational change within BRD4 dimers in vitro and in cancer cells.","method":"Integrative structural biology, biophysical analysis, in vitro CK2 phosphorylation, domain mutagenesis, bivalent inhibitor studies in cells","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — integrative structural biology with domain mutagenesis and in vitro phosphorylation assays, establishing the phosphorylation-dependent dimerization mechanism","pmids":["34754068"],"is_preprint":false},{"year":2021,"finding":"BRD4 is required for FXR-mediated regulation of bile acid homeostasis genes (including SHP and CYP7A1). Liver-specific downregulation of BRD4 disrupts bile acid homeostasis. FXR-activated corepressor SMRT decreases NF-κB binding at inflammatory genes in a BRD4-dependent manner.","method":"Liver-specific Brd4 knockdown in mice, gene expression analysis, ChIP, Co-immunoprecipitation of FXR-SMRT-BRD4 complexes","journal":"JCI insight","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD model combined with ChIP and Co-IP, single lab with two orthogonal methods","pmids":["33290278"],"is_preprint":false},{"year":2022,"finding":"BRD4 promotes DNA double-strand break resection and homologous recombination via interactions with the SWI/SNF chromatin remodeling complex and resection machinery, as established in a cell-free Xenopus egg extract system, independent of gene expression effects.","method":"Cell-free Xenopus egg extract reconstitution, biochemical DSB repair assays, BRD4 immunodepletion, SWI/SNF interaction assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 / Strong — cell-free reconstitution system in Xenopus extracts, biochemical immunodepletion, and protein-protein interaction assays, establishing gene expression-independent DSB repair function","pmids":["35641523"],"is_preprint":false},{"year":2022,"finding":"PRMT2 and PRMT4 methylate BRD4 at R179, R181, and R183, and this arginine methylation selectively promotes BRD4 recruitment to acetylated histones/chromatin for transcriptional regulation and DNA repair. DNA damage induces BRD4 arginine methylation, promoting its chromatin binding for DNA repair. BRD4 arginine methylation deficiency suppresses tumor growth.","method":"In vitro methylation assays, Co-IP, ChIP-seq, arginine-to-lysine point mutants, DNA damage assays, tumor growth assays","journal":"Science advances","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro methylation reconstitution, Co-IP, ChIP-seq, and structure-function analysis with point mutations, multiple orthogonal methods","pmids":["36475791"],"is_preprint":false},{"year":2022,"finding":"PRMT1 asymmetrically methylates BRD4 at R179/181/183 (the same sites also targeted by PRMT2/4), and PRMT1-mediated methylation promotes BRD4 phosphorylation. JMJD6 demethylase antagonizes this methylation. BRD4 R179/181/183K mutant cells show reduced ovarian cancer metastasis.","method":"In vitro methylation assays, Co-IP, phosphorylation analysis, arginine-to-lysine mutant expression, in vivo and in vitro invasion assays","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — in vitro methylation and Co-IP with functional point mutants, but single lab and partially overlapping with PRMT2/4 findings","pmids":["37737256"],"is_preprint":false},{"year":2022,"finding":"BRD4 bromodomains are dispensable for RNA polymerase II pause release. A minimal, bromodomain-less C-terminal BRD4 fragment containing the P-TEFb-interacting C-terminal motif (CTM) is both necessary and sufficient to mediate Pol II pause release in the absence of full-length BRD4, indicating a distinct bromodomain-independent BRD4-PTEFb population regulates transcription.","method":"Rapid protein depletion (degron system), genetic complementation with domain deletion mutants, nascent transcription analysis (PRO-seq), ChIP-seq","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — rapid depletion with domain-deletion complementation and nascent transcription profiling, multiple orthogonal methods establishing the CTM as the functional domain for Pol II pause release","pmids":["37442129"],"is_preprint":false},{"year":2023,"finding":"BRD4 transcriptional condensate formation is regulated by interplay between chromatin binding and self-assembly: BRD4-chromatin interactions control condensate nucleation rate and multivalent acetylated chromatin sites provide a platform for BRD4 clustering below concentrations required for off-chromatin condensation, providing a mechanism for selective condensate formation at acetylated chromatin regions.","method":"Live-cell imaging, coarse-grained simulations, BRD4 chromatin-binding mutant analysis, FRAP","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — live-cell experiments with computational modeling, mutant analysis, single study","pmids":["38656803"],"is_preprint":false},{"year":2024,"finding":"BRD4 plays a role in histone lactylation (H4K8la) in astrocytes. Targeted silencing of BRD4 in astrocytes significantly reduces H4K8la lactylation, aggravating A1 astrocyte polarization after subarachnoid hemorrhage, affecting neural function recovery.","method":"BRD4 siRNA silencing in vitro and in vivo, H4K8la western blot and immunofluorescence, astrocyte polarization assays, murine SAH model","journal":"Journal of neuroinflammation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo KD with direct histone lactylation readout, single lab, two orthogonal methods","pmids":["39080649"],"is_preprint":false},{"year":2021,"finding":"BRD4/CEBPD relationship: BRD4 (specifically its bromodomain-1) controls CEBPD expression via enhancer regulation. Endogenous BRD4 protein co-immunoprecipitates with CEBPD, and both proteins co-precipitate the Cebpd promoter and enhancer DNA, forming a BRD4/CEBPD/promoter/enhancer complex that mediates TNF-α-induced SMC inflammation via PDGFRα.","method":"ChIP-seq, Co-IP, BRD4 gene silencing, bromodomain-1 vs. -2 domain mutants, enhancer deletion, gain- and loss-of-function experiments","journal":"Molecular therapy. Methods & clinical development","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ChIP-seq, and domain-specific mutants in a single lab study","pmids":["33768129"],"is_preprint":false}],"current_model":"BRD4 is a double bromodomain-containing BET family protein that reads acetylated histones and non-histone proteins to regulate transcription elongation via P-TEFb/CDK9 recruitment, with its C-terminal motif (CTM) being necessary and sufficient for Pol II pause release independent of bromodomains; it has intrinsic kinase activity (phosphorylating MYC at Thr58 and RNA Pol II) and histone acetyltransferase activity, with JNK-mediated phosphorylation switching BRD4 between chromatin-bound HAT-active and promoter-associated kinase-active states; BRD4 forms liquid-liquid phase-separated condensates at acetylated super-enhancers, with condensation driven by intrinsically disordered regions and regulated by phosphorylation and chromatin binding; it recruits condensin II to insulate chromatin from DNA damage signaling, promotes homologous recombination via SWI/SNF interactions, prevents R-loop-mediated transcription-replication conflicts, and facilitates genome folding by stabilizing NIPBL/cohesin on chromatin; it is regulated post-translationally by CK2-mediated phosphorylation (inducing dimerization), PRMT1/2/4-mediated arginine methylation at R179/181/183 (promoting chromatin recruitment and DNA repair), and JMJD6-mediated demethylation; BRD4 has two isoforms with opposing functions in cancer (BRD4-S is oncogenic, BRD4-L is tumor-suppressive in breast cancer), and is targeted for proteasomal degradation by cereblon-based PROTACs."},"narrative":{"mechanistic_narrative":"BRD4 is a chromatin-associated regulator of transcription that reads acetylated histones through its double bromodomains and couples enhancer/super-enhancer activity to RNA polymerase II elongation by recruiting the P-TEFb elongation factor [PMID:17329240, PMID:27294782]. Its association with mitotic chromosomes—where it persists while most regulatory factors dissociate—underlies an essential role in the G2/M transition, and it serves as a cellular tether for viral genomes during mitosis [PMID:10938129, PMID:17329240]. BRD4 drives transcriptional pause release through a C-terminal motif (CTM) that binds P-TEFb; this bromodomain-less CTM fragment is necessary and sufficient for Pol II pause release, defining a chromatin-reading-independent transcriptional function, and the CTM–P-TEFb axis prevents R-loop accumulation and transcription–replication conflicts [PMID:37442129, PMID:32966794]. Beyond reading acetylation, BRD4 possesses intrinsic kinase activity that phosphorylates MYC at Thr58 to trigger its degradation and acts on RNA Pol II, as well as histone acetyltransferase activity; JNK-mediated phosphorylation at Thr1186/Thr1212 switches BRD4 between a chromatin-bound HAT-active state and a promoter-associated kinase-active state [PMID:32482868, PMID:39454579]. BRD4 assembles liquid-like nuclear condensates at acetylated super-enhancers, nucleated by intrinsically disordered regions and bromodomain–chromatin contacts and tuned by phosphorylation, providing selective compartmentalization at multivalent acetylated chromatin [PMID:32203489, PMID:38656803]. BRD4 is regulated post-translationally by CK2 phosphorylation, which promotes a phosphorylation-dependent dimerization, and by PRMT1/2/4 arginine methylation at R179/181/183, which enhances chromatin recruitment for transcription and DNA repair and is antagonized by JMJD6 [PMID:34754068, PMID:36475791, PMID:37737256]. It supports genome integrity and architecture by recruiting condensin II to insulate chromatin from DNA damage signaling, promoting double-strand-break resection and homologous recombination via SWI/SNF, and stabilizing NIPBL/cohesin to enable loop extrusion and genome folding [PMID:23728299, PMID:35641523, PMID:34611363]. Two isoforms have opposing roles in breast cancer, with BRD4-S oncogenic and BRD4-L tumor-suppressive, and BRD4 can be eliminated by cereblon-based PROTACs that more effectively suppress MYC than bromodomain inhibition alone [PMID:32446320, PMID:26051217].","teleology":[{"year":2000,"claim":"Established that BRD4 is a chromatin-retained factor with a cell-cycle function, answering whether it acts during mitosis rather than only in interphase transcription.","evidence":"Immunofluorescence/live-cell imaging plus microinjection of neutralizing anti-BRD4 antibody and cell cycle analysis in HeLa cells","pmids":["10938129"],"confidence":"High","gaps":["Molecular partners mediating mitotic chromosome retention not defined","Link to transcriptional function not yet established at this stage"]},{"year":2007,"claim":"Defined the core transcriptional mechanism—bromodomain reading of acetylated chromatin and recruitment of P-TEFb/Mediator—and a viral-tethering adaptor role, framing BRD4 as a transcription elongation factor.","evidence":"Co-immunoprecipitation, transcriptional reporter assays, and biochemical fractionation (review synthesizing prior experimental work)","pmids":["17329240"],"confidence":"Medium","gaps":["Domain dependence of P-TEFb recruitment not dissected","Quantitative contribution to elongation versus initiation unresolved"]},{"year":2013,"claim":"Showed BRD4 actively restrains DNA damage signaling via condensin II recruitment, extending its role from transcription to chromatin compaction and the DDR.","evidence":"High-content RNAi screen with loss/gain-of-function, chromatin compaction and irradiation survival assays","pmids":["23728299"],"confidence":"High","gaps":["Isoform specificity of the effect not fully resolved","Direct condensin II contact interface not mapped"]},{"year":2015,"claim":"Demonstrated that targeted degradation of BRD4 differs functionally from bromodomain inhibition, establishing a degrader strategy and revealing inhibitor-induced protein accumulation.","evidence":"PROTAC (ARV-825)-mediated cereblon recruitment, western blot, viability and apoptosis assays across cell lines","pmids":["26051217"],"confidence":"High","gaps":["Degron site preferences on BRD4 not defined","In vivo durability of degradation not assessed here"]},{"year":2016,"claim":"Connected BRD4 chromatin binding to upstream histone modifications (DOT1L/H3K79me2-driven H4 acetylation) and to heat-stress splicing and CK2/PP2A regulation, broadening its regulatory inputs.","evidence":"Quantitative/chemoproteomics, fractionation, ChIP-seq, genetics (DOT1L); Co-IP and RNA-seq (HSF1/splicing); kinase/phosphatase assays (CK2/PP2A)","pmids":["27294782","27536004","27769352"],"confidence":"High","gaps":["Whether CK2/PP2A regulation and splicing roles share a common mechanism unclear","Direct vs indirect effects of DOT1L on BRD4 occupancy not fully separated"]},{"year":2017,"claim":"Revealed context-specific and repressive transcriptional roles—silencing autophagy/lysosomal genes via G9a and driving myogenic gene programs—showing BRD4 is not uniformly an activator.","evidence":"Knockdown, ChIP, reciprocal Co-IP, AMPK/SIRT1 manipulation (autophagy); BET-protein-specific RNAi and ChIP at Myog (myogenesis)","pmids":["28525743","28733670"],"confidence":"High","gaps":["Determinants selecting activation versus repression at a given locus unknown","BRD4 vs BRD3 functional divergence mechanism unresolved"]},{"year":2018,"claim":"Linked BRD4 to replication-checkpoint control through association with CDC6 and CHK1 signaling, adding a replication-stress arm to its genome-maintenance functions.","evidence":"Co-IP, JQ1/AZD5153 inhibition, CHK1 phosphorylation and replication assays, xenografts","pmids":["29636547"],"confidence":"Medium","gaps":["Direct vs transcription-mediated effect on the checkpoint not separated","Reciprocal validation of BRD4-CDC6 interaction limited"]},{"year":2019,"claim":"Defined signal-responsive genome-wide redistribution and tissue-specific requirements of BRD4, plus a nuclear metabolic partnership with MTHFD1, establishing it as a context-dependent enhancer effector.","evidence":"ChIP-seq/RNA-seq/mass-spec in TGF-β-stimulated fibroblasts; conditional Brd4 KO mice (hematopoiesis/macrophages); interaction screens and metabolomics (MTHFD1); zebrafish ZGA gain/loss-of-function with P300; Co-IP of BRD4-IRF1-P-TEFb-RNAPII at MLKL","pmids":["31409188","30842097","31133746","31211993","30644439"],"confidence":"High","gaps":["Why some super-enhancers are BRD4-independent (compensatory) is unexplained","Mechanism of MTHFD1 nuclear recruitment to specific loci not defined"]},{"year":2020,"claim":"Established BRD4 as a phase-separating, dual-isoform protein with intrinsic MYC-directed kinase activity and an R-loop-suppressing CTM–P-TEFb function, integrating biophysics, enzymology, and genome stability.","evidence":"FRAP/live imaging and isoform-specific KD (condensates, isoform functions); in vitro kinase/HAT and ubiquitination assays (MYC Thr58); DRIP-seq and domain mutants (R-loops); inhibitor/HIF1α/CSF1 tumor models","pmids":["32203489","32446320","32482868","32966794","32286255"],"confidence":"High","gaps":["Catalytic identity/structure of the BRD4 kinase module not resolved","How condensate formation mechanistically couples to elongation unclear"]},{"year":2021,"claim":"Mapped post-translational and architectural control of BRD4—CK2-driven dimerization, arginine methylation–regulated recruitment, NIPBL/cohesin stabilization for genome folding, and adaptor-mediated chromatin retention—plus differentiation roles.","evidence":"Integrative structural biology and CK2 assays (dimerization); in vitro methylation/Co-IP/ChIP-seq with R-to-K mutants (PRMT1/2/4, JMJD6); Co-IP, Hi-C, point mutations and WAPL rescue (NIPBL); SEC/MS/Co-IP (ASXL3); conditional KO and ChIP-seq (CD8 T cells); ChIP/Co-IP (FXR, CEBPD)","pmids":["34754068","36475791","37737256","34611363","32669118","34037670","33290278","33768129"],"confidence":"High","gaps":["How dimerization, methylation, and condensation are coordinated is unresolved","Structural basis of the NIPBL and ASXL3 (ET-domain BBM) interactions partially defined"]},{"year":2022,"claim":"Resolved that BRD4 promotes HR-directed DSB repair biochemically via SWI/SNF, independent of transcription, and that JNK phosphorylation toggles its HAT versus kinase activities, separating its enzymatic states.","evidence":"Cell-free Xenopus extract reconstitution and immunodepletion (HR/SWI/SNF); in vitro kinase/HAT assays with phospho-mutants and JNK modulation (activity switch)","pmids":["35641523","39454579"],"confidence":"High","gaps":["Whether the kinase/HAT switch operates at endogenous physiological stoichiometry in vivo unclear","Direct SWI/SNF contact interface on BRD4 not mapped"]},{"year":2023,"claim":"Showed bromodomains are dispensable for Pol II pause release, isolating the CTM–P-TEFb module as the necessary and sufficient elongation effector, and refined the chromatin-versus-self-assembly logic of condensate nucleation.","evidence":"Degron depletion with domain-deletion complementation and PRO-seq/ChIP-seq (CTM); live imaging, FRAP, chromatin-binding mutants and simulations (condensate nucleation)","pmids":["37442129","38656803"],"confidence":"High","gaps":["How the bromodomain-dependent and bromodomain-independent BRD4 pools are partitioned in cells unknown","In vivo relevance of off-chromatin condensation thresholds untested"]},{"year":2024,"claim":"Extended BRD4 function to histone lactylation, linking it to H4K8la deposition and astrocyte polarization in injury, suggesting broader histone-acylation reader/effector roles.","evidence":"BRD4 siRNA in vitro/in vivo, H4K8la western/immunofluorescence, astrocyte polarization in a murine subarachnoid hemorrhage model","pmids":["39080649"],"confidence":"Medium","gaps":["Whether BRD4 directly recognizes or enzymatically promotes lactylation not established","Mechanism connecting BRD4 to A1 polarization undefined"]},{"year":null,"claim":"The structural and catalytic basis of BRD4's intrinsic kinase and HAT activities, and how its enzymatic, dimerization, methylation, and phase-separation states are integrated to select genomic targets, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No reported structure of the BRD4 kinase or HAT catalytic module","Interplay among PTMs, dimerization, and condensation in target selection not mechanistically integrated","Determinants of activator versus repressor behavior at individual loci unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0042393","term_label":"histone binding","supporting_discovery_ids":[1,4,27]},{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[1,7,29]},{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[16,22]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[16,22]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[1,20,21]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[15]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,15,22]},{"term_id":"GO:0000228","term_label":"nuclear chromosome","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[10,15]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[1,4,29]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,15,21]},{"term_id":"R-HSA-73894","term_label":"DNA Repair","supporting_discovery_ids":[2,26,27]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,9]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,22]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[8,14,21,23]}],"complexes":["P-TEFb elongation complex","Mediator","condensin II","SWI/SNF"],"partners":["CDK9","NIPBL","MTHFD1","ASXL3","HSF1","CDC6","IRF1","CEBPD"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O60885","full_name":"Bromodomain-containing protein 4","aliases":["Protein HUNK1"],"length_aa":1362,"mass_kda":152.2,"function":"Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation (PubMed:20871596, PubMed:23086925, PubMed:23317504, PubMed:29176719, PubMed:29379197). Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure (PubMed:22334664, PubMed:23317504, PubMed:23589332). During interphase, plays a key role in regulating the transcription of signal-inducible genes by associating with the P-TEFb complex and recruiting it to promoters (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). Also recruits P-TEFb complex to distal enhancers, so called anti-pause enhancers in collaboration with JMJD6 (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). BRD4 and JMJD6 are required to form the transcriptionally active P-TEFb complex by displacing negative regulators such as HEXIM1 and 7SKsnRNA complex from P-TEFb, thereby transforming it into an active form that can then phosphorylate the C-terminal domain (CTD) of RNA polymerase II (PubMed:16109376, PubMed:16109377, PubMed:19596240, PubMed:23589332, PubMed:24360279). Regulates differentiation of naive CD4(+) T-cells into T-helper Th17 by promoting recruitment of P-TEFb to promoters (By similarity). Promotes phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II (PubMed:23086925). According to a report, directly acts as an atypical protein kinase and mediates phosphorylation of 'Ser-2' of the C-terminal domain (CTD) of RNA polymerase II; these data however need additional evidences in vivo (PubMed:22509028). In addition to acetylated histones, also recognizes and binds acetylated RELA, leading to further recruitment of the P-TEFb complex and subsequent activation of NF-kappa-B (PubMed:19103749). Also acts as a regulator of p53/TP53-mediated transcription: following phosphorylation by CK2, recruited to p53/TP53 specific target promoters (PubMed:23317504) Acts as a chromatin insulator in the DNA damage response pathway. Inhibits DNA damage response signaling by recruiting the condensin-2 complex to acetylated histones, leading to chromatin structure remodeling, insulating the region from DNA damage response by limiting spreading of histone H2AX/H2A.x phosphorylation","subcellular_location":"Chromosome","url":"https://www.uniprot.org/uniprotkb/O60885/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/BRD4","classification":"Common Essential","n_dependent_lines":1150,"n_total_lines":1208,"dependency_fraction":0.9519867549668874},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000141867","cell_line_id":"CID001135","localizations":[{"compartment":"nucleoplasm","grade":3},{"compartment":"nuclear_punctae","grade":2}],"interactors":[{"gene":"BLVRA","stoichiometry":0.2},{"gene":"HIST2H2BE","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001135","total_profiled":1310},"omim":[{"mim_id":"620568","title":"CORNELIA DE LANGE SYNDROME 6; CDLS6","url":"https://www.omim.org/entry/620568"},{"mim_id":"620524","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 16; DCAF16","url":"https://www.omim.org/entry/620524"},{"mim_id":"619325","title":"COFFIN-SIRIS SYNDROME 12; CSS12","url":"https://www.omim.org/entry/619325"},{"mim_id":"618829","title":"NABAIS SA-DE VRIES SYNDROME, TYPE 2; NSDVS2","url":"https://www.omim.org/entry/618829"},{"mim_id":"618828","title":"NABAIS SA-DE VRIES SYNDROME, TYPE 1; NSDVS1","url":"https://www.omim.org/entry/618828"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoplasm","reliability":"Enhanced"},{"location":"Mitotic chromosome","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/BRD4"},"hgnc":{"alias_symbol":["HUNKI","MCAP","CAP","HUNK1","FSHRG4"],"prev_symbol":[]},"alphafold":{"accession":"O60885","domains":[{"cath_id":"1.20.920.10","chopping":"48-173","consensus_level":"medium","plddt":94.3133,"start":48,"end":173},{"cath_id":"1.20.920.10","chopping":"351-460","consensus_level":"medium","plddt":94.7535,"start":351,"end":460},{"cath_id":"1.20.1270.220","chopping":"613-674","consensus_level":"high","plddt":85.0719,"start":613,"end":674}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O60885","model_url":"https://alphafold.ebi.ac.uk/files/AF-O60885-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O60885-F1-predicted_aligned_error_v6.png","plddt_mean":55.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BRD4","jax_strain_url":"https://www.jax.org/strain/search?query=BRD4"},"sequence":{"accession":"O60885","fasta_url":"https://rest.uniprot.org/uniprotkb/O60885.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O60885/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O60885"}},"corpus_meta":[{"pmid":"26051217","id":"PMC_26051217","title":"Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4.","date":"2015","source":"Chemistry & biology","url":"https://pubmed.ncbi.nlm.nih.gov/26051217","citation_count":892,"is_preprint":false},{"pmid":"30466442","id":"PMC_30466442","title":"BRD4 and Cancer: going beyond transcriptional regulation.","date":"2018","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30466442","citation_count":588,"is_preprint":false},{"pmid":"17329240","id":"PMC_17329240","title":"The double bromodomain-containing chromatin adaptor Brd4 and transcriptional regulation.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17329240","citation_count":558,"is_preprint":false},{"pmid":"23728299","id":"PMC_23728299","title":"The bromodomain protein Brd4 insulates chromatin from DNA damage signalling.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/23728299","citation_count":269,"is_preprint":false},{"pmid":"32338867","id":"PMC_32338867","title":"Antibody-PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4.","date":"2020","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32338867","citation_count":256,"is_preprint":false},{"pmid":"10938129","id":"PMC_10938129","title":"A bromodomain protein, MCAP, associates with mitotic chromosomes and affects G(2)-to-M transition.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10938129","citation_count":253,"is_preprint":false},{"pmid":"28525743","id":"PMC_28525743","title":"Bromodomain Protein BRD4 Is a Transcriptional Repressor of Autophagy and Lysosomal Function.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/28525743","citation_count":209,"is_preprint":false},{"pmid":"31409188","id":"PMC_31409188","title":"Dynamic Chromatin Targeting of BRD4 Stimulates Cardiac Fibroblast Activation.","date":"2019","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/31409188","citation_count":155,"is_preprint":false},{"pmid":"32286255","id":"PMC_32286255","title":"Potent BRD4 inhibitor suppresses cancer cell-macrophage interaction.","date":"2020","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/32286255","citation_count":145,"is_preprint":false},{"pmid":"29415456","id":"PMC_29415456","title":"BET Family Protein BRD4: An Emerging Actor in NFκB Signaling in Inflammation and Cancer.","date":"2018","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/29415456","citation_count":145,"is_preprint":false},{"pmid":"32446320","id":"PMC_32446320","title":"Opposing Functions of BRD4 Isoforms in Breast Cancer.","date":"2020","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/32446320","citation_count":141,"is_preprint":false},{"pmid":"32203489","id":"PMC_32203489","title":"Roles of the BRD4 short isoform in phase separation and active gene transcription.","date":"2020","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/32203489","citation_count":135,"is_preprint":false},{"pmid":"32482868","id":"PMC_32482868","title":"MYC protein stability is negatively regulated by BRD4.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32482868","citation_count":127,"is_preprint":false},{"pmid":"30542529","id":"PMC_30542529","title":"Targeting Brd4 for cancer therapy: inhibitors and degraders.","date":"2018","source":"MedChemComm","url":"https://pubmed.ncbi.nlm.nih.gov/30542529","citation_count":126,"is_preprint":false},{"pmid":"23592320","id":"PMC_23592320","title":"Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.","date":"2013","source":"American journal of medical genetics. Part C, Seminars in medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23592320","citation_count":124,"is_preprint":false},{"pmid":"35646539","id":"PMC_35646539","title":"Autophagy enhanced by curcumin ameliorates inflammation in atherogenesis via the TFEB-P300-BRD4 axis.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35646539","citation_count":112,"is_preprint":false},{"pmid":"30842097","id":"PMC_30842097","title":"BRD4 directs hematopoietic stem cell development and modulates macrophage inflammatory responses.","date":"2019","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/30842097","citation_count":111,"is_preprint":false},{"pmid":"31211993","id":"PMC_31211993","title":"Brd4 and P300 Confer Transcriptional Competency during Zygotic Genome Activation.","date":"2019","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/31211993","citation_count":109,"is_preprint":false},{"pmid":"30832981","id":"PMC_30832981","title":"Emerging roles of and therapeutic strategies targeting BRD4 in cancer.","date":"2019","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30832981","citation_count":108,"is_preprint":false},{"pmid":"24763052","id":"PMC_24763052","title":"The bromodomain protein BRD4 regulates the KEAP1/NRF2-dependent oxidative stress response.","date":"2014","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/24763052","citation_count":101,"is_preprint":false},{"pmid":"27294782","id":"PMC_27294782","title":"Functional interdependence of BRD4 and DOT1L in MLL leukemia.","date":"2016","source":"Nature structural & molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27294782","citation_count":92,"is_preprint":false},{"pmid":"29636547","id":"PMC_29636547","title":"BRD4 facilitates replication stress-induced DNA damage response.","date":"2018","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/29636547","citation_count":81,"is_preprint":false},{"pmid":"32966794","id":"PMC_32966794","title":"BRD4 Prevents R-Loop Formation and Transcription-Replication Conflicts by Ensuring Efficient Transcription Elongation.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32966794","citation_count":80,"is_preprint":false},{"pmid":"23131666","id":"PMC_23131666","title":"Two faces of brd4: mitotic bookmark and transcriptional lynchpin.","date":"2012","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/23131666","citation_count":77,"is_preprint":false},{"pmid":"36539410","id":"PMC_36539410","title":"Regulation of programmed cell death by Brd4.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36539410","citation_count":75,"is_preprint":false},{"pmid":"38135679","id":"PMC_38135679","title":"Super-enhancers and the super-enhancer reader BRD4: tumorigenic factors and therapeutic targets.","date":"2023","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38135679","citation_count":72,"is_preprint":false},{"pmid":"33452461","id":"PMC_33452461","title":"Supercharging BRD4 with NUT in carcinoma.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33452461","citation_count":71,"is_preprint":false},{"pmid":"31133746","id":"PMC_31133746","title":"MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation.","date":"2019","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/31133746","citation_count":71,"is_preprint":false},{"pmid":"34611363","id":"PMC_34611363","title":"BRD4 orchestrates genome folding to promote neural crest differentiation.","date":"2021","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34611363","citation_count":69,"is_preprint":false},{"pmid":"26191363","id":"PMC_26191363","title":"BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.","date":"2015","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/26191363","citation_count":69,"is_preprint":false},{"pmid":"33162822","id":"PMC_33162822","title":"Targeting BRD4 prevents acute gouty arthritis by regulating pyroptosis.","date":"2020","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33162822","citation_count":66,"is_preprint":false},{"pmid":"24592384","id":"PMC_24592384","title":"Brd4 and HEXIM1: multiple roles in P-TEFb regulation and cancer.","date":"2014","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/24592384","citation_count":66,"is_preprint":false},{"pmid":"28391274","id":"PMC_28391274","title":"Inhibition of BRD4 Suppresses Cell Proliferation and Induces Apoptosis in Renal Cell Carcinoma.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/28391274","citation_count":62,"is_preprint":false},{"pmid":"25146928","id":"PMC_25146928","title":"BRD4 regulates Nanog expression in mouse embryonic stem cells and preimplantation embryos.","date":"2014","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/25146928","citation_count":61,"is_preprint":false},{"pmid":"32544088","id":"PMC_32544088","title":"Brd4-p300 inhibition downregulates Nox4 and accelerates lung fibrosis resolution in aged mice.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/32544088","citation_count":60,"is_preprint":false},{"pmid":"32502863","id":"PMC_32502863","title":"Novel strategies targeting bromodomain-containing protein 4 (BRD4) for cancer drug discovery.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32502863","citation_count":58,"is_preprint":false},{"pmid":"35866356","id":"PMC_35866356","title":"BRD4 and MYC: power couple in transcription and disease.","date":"2022","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/35866356","citation_count":57,"is_preprint":false},{"pmid":"34697817","id":"PMC_34697817","title":"BRD4 in physiology and pathology: ''BET'' on its partners.","date":"2021","source":"BioEssays : news and reviews in molecular, cellular and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/34697817","citation_count":55,"is_preprint":false},{"pmid":"31734632","id":"PMC_31734632","title":"Targeting bromodomain-containing protein 4 (BRD4) inhibits MYC expression in colorectal cancer cells.","date":"2019","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31734632","citation_count":52,"is_preprint":false},{"pmid":"28549889","id":"PMC_28549889","title":"Synthesis and evaluation of novel dual BRD4/HDAC inhibitors.","date":"2017","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/28549889","citation_count":52,"is_preprint":false},{"pmid":"37156794","id":"PMC_37156794","title":"BRD4-targeting PROTAC as a unique tool to study biomolecular condensates.","date":"2023","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/37156794","citation_count":51,"is_preprint":false},{"pmid":"32669118","id":"PMC_32669118","title":"ASXL3 bridges BRD4 to BAP1 complex and governs enhancer activity in small cell lung cancer.","date":"2020","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32669118","citation_count":51,"is_preprint":false},{"pmid":"27536004","id":"PMC_27536004","title":"The bromodomain protein BRD4 regulates splicing during heat shock.","date":"2016","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27536004","citation_count":50,"is_preprint":false},{"pmid":"33712705","id":"PMC_33712705","title":"BRD4 inhibition sensitizes cervical cancer to radiotherapy by attenuating DNA repair.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/33712705","citation_count":49,"is_preprint":false},{"pmid":"28721198","id":"PMC_28721198","title":"BRD4 inhibition for the treatment of pathological organ fibrosis.","date":"2017","source":"F1000Research","url":"https://pubmed.ncbi.nlm.nih.gov/28721198","citation_count":49,"is_preprint":false},{"pmid":"37442129","id":"PMC_37442129","title":"Distinct layers of BRD4-PTEFb reveal bromodomain-independent function in transcriptional regulation.","date":"2023","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/37442129","citation_count":47,"is_preprint":false},{"pmid":"27769352","id":"PMC_27769352","title":"Phospho-BRD4: transcription plasticity and drug targeting.","date":"2016","source":"Drug discovery today. Technologies","url":"https://pubmed.ncbi.nlm.nih.gov/27769352","citation_count":47,"is_preprint":false},{"pmid":"31815566","id":"PMC_31815566","title":"A patent review of BRD4 inhibitors (2013-2019).","date":"2019","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/31815566","citation_count":47,"is_preprint":false},{"pmid":"27965149","id":"PMC_27965149","title":"Involvement of Brd4 in different steps of the papillomavirus life cycle.","date":"2016","source":"Virus research","url":"https://pubmed.ncbi.nlm.nih.gov/27965149","citation_count":46,"is_preprint":false},{"pmid":"39080649","id":"PMC_39080649","title":"Lactylation of histone by BRD4 regulates astrocyte polarization after experimental subarachnoid hemorrhage.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/39080649","citation_count":45,"is_preprint":false},{"pmid":"15539109","id":"PMC_15539109","title":"Brd4: tethering, segregation and beyond.","date":"2004","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/15539109","citation_count":45,"is_preprint":false},{"pmid":"29662175","id":"PMC_29662175","title":"Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity.","date":"2018","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/29662175","citation_count":45,"is_preprint":false},{"pmid":"26093279","id":"PMC_26093279","title":"Targeting bromodomain-containing protein 4 (BRD4) benefits rheumatoid arthritis.","date":"2015","source":"Immunology letters","url":"https://pubmed.ncbi.nlm.nih.gov/26093279","citation_count":44,"is_preprint":false},{"pmid":"36047906","id":"PMC_36047906","title":"BRD4: a general regulator of transcription elongation.","date":"2022","source":"Transcription","url":"https://pubmed.ncbi.nlm.nih.gov/36047906","citation_count":43,"is_preprint":false},{"pmid":"35641523","id":"PMC_35641523","title":"BRD4 promotes resection and homology-directed repair of DNA double-strand breaks.","date":"2022","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/35641523","citation_count":43,"is_preprint":false},{"pmid":"33851008","id":"PMC_33851008","title":"BRD4: An emerging prospective therapeutic target in glioma.","date":"2021","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/33851008","citation_count":42,"is_preprint":false},{"pmid":"35154163","id":"PMC_35154163","title":"BRD4 Inhibition Attenuates Inflammatory Pain by Ameliorating NLRP3 Inflammasome-Induced Pyroptosis.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35154163","citation_count":42,"is_preprint":false},{"pmid":"35402244","id":"PMC_35402244","title":"Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35402244","citation_count":41,"is_preprint":false},{"pmid":"36538950","id":"PMC_36538950","title":"Brd4 proteolysis-targeting chimera nanoparticles sensitized colorectal cancer chemotherapy.","date":"2023","source":"Journal of controlled release : official journal of the Controlled Release Society","url":"https://pubmed.ncbi.nlm.nih.gov/36538950","citation_count":40,"is_preprint":false},{"pmid":"33850013","id":"PMC_33850013","title":"Brd4-bound enhancers drive cell-intrinsic sex differences in glioblastoma.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33850013","citation_count":40,"is_preprint":false},{"pmid":"36475791","id":"PMC_36475791","title":"Arginine methylation of BRD4 by PRMT2/4 governs transcription and DNA repair.","date":"2022","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/36475791","citation_count":40,"is_preprint":false},{"pmid":"30153557","id":"PMC_30153557","title":"Dual BRD4 and AURKA Inhibition Is Synergistic against MYCN-Amplified and Nonamplified Neuroblastoma.","date":"2018","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/30153557","citation_count":38,"is_preprint":false},{"pmid":"38277141","id":"PMC_38277141","title":"Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38277141","citation_count":37,"is_preprint":false},{"pmid":"28854735","id":"PMC_28854735","title":"BRD4 inhibitors block telomere elongation.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/28854735","citation_count":37,"is_preprint":false},{"pmid":"28733670","id":"PMC_28733670","title":"BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis.","date":"2017","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/28733670","citation_count":37,"is_preprint":false},{"pmid":"37819236","id":"PMC_37819236","title":"The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/37819236","citation_count":35,"is_preprint":false},{"pmid":"32409773","id":"PMC_32409773","title":"The therapeutic potential of BRD4 in cardiovascular disease.","date":"2020","source":"Hypertension research : official journal of the Japanese Society of Hypertension","url":"https://pubmed.ncbi.nlm.nih.gov/32409773","citation_count":33,"is_preprint":false},{"pmid":"28837371","id":"PMC_28837371","title":"BRD4 is a newly characterized transcriptional regulator that represses autophagy and lysosomal function.","date":"2017","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/28837371","citation_count":32,"is_preprint":false},{"pmid":"30644439","id":"PMC_30644439","title":"The bromodomain protein BRD4 positively regulates necroptosis via modulating MLKL expression.","date":"2019","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30644439","citation_count":32,"is_preprint":false},{"pmid":"34910943","id":"PMC_34910943","title":"MED12 and BRD4 cooperate to sustain cancer growth upon loss of mediator kinase.","date":"2021","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/34910943","citation_count":31,"is_preprint":false},{"pmid":"34750516","id":"PMC_34750516","title":"BRD4 drives esophageal squamous cell carcinoma growth by promoting RCC2 expression.","date":"2021","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/34750516","citation_count":30,"is_preprint":false},{"pmid":"34037670","id":"PMC_34037670","title":"Bromodomain protein BRD4 directs and sustains CD8 T cell differentiation during infection.","date":"2021","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34037670","citation_count":30,"is_preprint":false},{"pmid":"34438075","id":"PMC_34438075","title":"Dual-target inhibitors of bromodomain-containing protein 4 (BRD4) in cancer therapy: Current situation and future directions.","date":"2021","source":"Drug discovery today","url":"https://pubmed.ncbi.nlm.nih.gov/34438075","citation_count":30,"is_preprint":false},{"pmid":"25647019","id":"PMC_25647019","title":"BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance.","date":"2015","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/25647019","citation_count":30,"is_preprint":false},{"pmid":"37096681","id":"PMC_37096681","title":"YAP/BRD4-controlled ROR1 promotes tumor-initiating cells and hyperproliferation in pancreatic cancer.","date":"2023","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/37096681","citation_count":28,"is_preprint":false},{"pmid":"38656803","id":"PMC_38656803","title":"Interplay of condensation and chromatin binding underlies BRD4 targeting.","date":"2024","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/38656803","citation_count":28,"is_preprint":false},{"pmid":"30664982","id":"PMC_30664982","title":"B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma.","date":"2019","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30664982","citation_count":27,"is_preprint":false},{"pmid":"27980063","id":"PMC_27980063","title":"BRD4 promotes p63 and GRHL3 expression downstream of FOXO in mammary epithelial cells.","date":"2017","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/27980063","citation_count":27,"is_preprint":false},{"pmid":"33290278","id":"PMC_33290278","title":"BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.","date":"2020","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/33290278","citation_count":27,"is_preprint":false},{"pmid":"37737256","id":"PMC_37737256","title":"Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37737256","citation_count":26,"is_preprint":false},{"pmid":"32163373","id":"PMC_32163373","title":"ARV-825-induced BRD4 protein degradation as a therapy for thyroid carcinoma.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32163373","citation_count":26,"is_preprint":false},{"pmid":"39341093","id":"PMC_39341093","title":"Exploration of the tunability of BRD4 degradation by DCAF16 trans-labelling covalent glues.","date":"2024","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39341093","citation_count":25,"is_preprint":false},{"pmid":"33413475","id":"PMC_33413475","title":"Modulation of BRD4 in HIV epigenetic regulation: implications for finding an HIV cure.","date":"2021","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/33413475","citation_count":24,"is_preprint":false},{"pmid":"35247919","id":"PMC_35247919","title":"Therapeutic Targeting of EZH2 and BET BRD4 in Pediatric Rhabdoid Tumors.","date":"2022","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/35247919","citation_count":24,"is_preprint":false},{"pmid":"35513563","id":"PMC_35513563","title":"Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.","date":"2022","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/35513563","citation_count":23,"is_preprint":false},{"pmid":"33768129","id":"PMC_33768129","title":"A hierarchical and collaborative BRD4/CEBPD partnership governs vascular smooth muscle cell inflammation.","date":"2021","source":"Molecular therapy. Methods & clinical development","url":"https://pubmed.ncbi.nlm.nih.gov/33768129","citation_count":23,"is_preprint":false},{"pmid":"34754068","id":"PMC_34754068","title":"Phosphorylation-dependent BRD4 dimerization and implications for therapeutic inhibition of BET family proteins.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34754068","citation_count":22,"is_preprint":false},{"pmid":"32331282","id":"PMC_32331282","title":"RSV Reprograms the CDK9•BRD4 Chromatin Remodeling Complex to Couple Innate Inflammation to Airway Remodeling.","date":"2020","source":"Viruses","url":"https://pubmed.ncbi.nlm.nih.gov/32331282","citation_count":22,"is_preprint":false},{"pmid":"36710583","id":"PMC_36710583","title":"Bromodomain-containing protein 4 (BRD4): a key player in inflammatory bowel disease and potential to inspire epigenetic therapeutics.","date":"2023","source":"Expert opinion on therapeutic targets","url":"https://pubmed.ncbi.nlm.nih.gov/36710583","citation_count":21,"is_preprint":false},{"pmid":"35072011","id":"PMC_35072011","title":"A natural product targets BRD4 to inhibit phase separation and gene transcription.","date":"2021","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/35072011","citation_count":21,"is_preprint":false},{"pmid":"34353856","id":"PMC_34353856","title":"miR-766-5p Targets Super-Enhancers by Downregulating CBP and BRD4.","date":"2021","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34353856","citation_count":21,"is_preprint":false},{"pmid":"39219068","id":"PMC_39219068","title":"An updated patent review of BRD4 degraders.","date":"2024","source":"Expert opinion on therapeutic patents","url":"https://pubmed.ncbi.nlm.nih.gov/39219068","citation_count":20,"is_preprint":false},{"pmid":"37820788","id":"PMC_37820788","title":"BRD4 Regulates Glycolysis-Dependent Nos2 Expression in Macrophages Upon H pylori Infection.","date":"2023","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37820788","citation_count":20,"is_preprint":false},{"pmid":"39454579","id":"PMC_39454579","title":"Phosphorylation by JNK switches BRD4 functions.","date":"2024","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/39454579","citation_count":19,"is_preprint":false},{"pmid":"39215370","id":"PMC_39215370","title":"BRD4: an effective target for organ fibrosis.","date":"2024","source":"Biomarker research","url":"https://pubmed.ncbi.nlm.nih.gov/39215370","citation_count":19,"is_preprint":false},{"pmid":"38721770","id":"PMC_38721770","title":"A BRD4-Targeting Photothermal Agent for Controlled Protein Degradation.","date":"2024","source":"Angewandte Chemie (International ed. in English)","url":"https://pubmed.ncbi.nlm.nih.gov/38721770","citation_count":19,"is_preprint":false},{"pmid":"32361153","id":"PMC_32361153","title":"Development of small-molecule BRD4 degraders based on pyrrolopyridone derivative.","date":"2020","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32361153","citation_count":19,"is_preprint":false},{"pmid":"38822666","id":"PMC_38822666","title":"BRD4 degraders may effectively counteract therapeutic resistance of leukemic stem cells in AML and ALL.","date":"2024","source":"American journal of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/38822666","citation_count":18,"is_preprint":false},{"pmid":"36563515","id":"PMC_36563515","title":"Design, synthesis, and biological evaluation of BRD4 degraders.","date":"2022","source":"Bioorganic & medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/36563515","citation_count":18,"is_preprint":false},{"pmid":"36499487","id":"PMC_36499487","title":"Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36499487","citation_count":18,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":44649,"output_tokens":8505,"usd":0.130761,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":18290,"output_tokens":5400,"usd":0.113225,"stage2_stop_reason":"end_turn"},"total_usd":0.243986,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"BRD4 (MCAP) associates with mitotic chromosomes during cell division, remaining chromosome-bound while most nuclear regulatory factors are released into the cytoplasm. Microinjection of anti-BRD4 antibody into HeLa cell nuclei completely inhibited entry into mitosis without abrogating ongoing DNA replication, establishing a role in G2/M transition.\",\n      \"method\": \"Immunofluorescence/live-cell imaging, microinjection of neutralizing antibody, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct loss-of-function (antibody microinjection) with specific mitotic phenotype, replicated by localization experiments across multiple conditions\",\n      \"pmids\": [\"10938129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"BRD4 binds to acetylated chromatin via its double bromodomains and is found in transcription complexes including Mediator and P-TEFb elongation factor, stimulating HIV-1 transcription in a Tat-independent manner. BRD4 also serves as a cellular adaptor for papillomavirus E2 protein, tethering viral genomes to mitotic chromosomes to facilitate viral genome segregation during mitosis.\",\n      \"method\": \"Co-immunoprecipitation, transcriptional reporter assays, biochemical fractionation\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — review synthesizing multiple Co-IP and functional studies from several labs; P-TEFb and Mediator associations are well-established but this paper is a review summarizing prior experimental work\",\n      \"pmids\": [\"17329240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A specific isoform of BRD4 functions as an endogenous inhibitor of DNA damage response signaling by recruiting the condensin II chromatin remodeling complex to acetylated histones via bromodomain interactions. Loss of this isoform results in relaxed chromatin, rapid checkpoint recovery and enhanced survival after irradiation; gain of function compacted chromatin and attenuated DNA damage signaling.\",\n      \"method\": \"High-content multiplex RNAi screen, loss-of-function and gain-of-function experiments, chromatin compaction assays, irradiation survival assays\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genome-wide RNAi screen with mechanistic follow-up showing direct recruitment of condensin II, complementary loss- and gain-of-function experiments with specific phenotypic readouts\",\n      \"pmids\": [\"23728299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BRD4 can be recruited to the E3 ubiquitin ligase cereblon via a PROTAC (ARV-825), leading to ubiquitin-mediated proteasomal degradation of BRD4. BRD4 inhibition (without degradation) leads to robust BRD4 protein accumulation, whereas degradation more effectively suppresses c-MYC levels and downstream signaling.\",\n      \"method\": \"PROTAC-mediated targeted protein degradation, western blot, cell viability and apoptosis assays\",\n      \"journal\": \"Chemistry & biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — reconstitution of ubiquitin-mediated degradation using bifunctional molecule, replicated across multiple cell lines with orthogonal mechanistic readouts\",\n      \"pmids\": [\"26051217\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRD4 and DOT1L exist in separate native protein complexes. DOT1L-mediated H3K79 dimethylation facilitates histone H4 acetylation, which in turn regulates BRD4 binding to chromatin. Genetic or pharmacological disruption of BRD4 and DOT1L showed synergistic activity against MLL leukemia, establishing a functional collaboration at highly transcribed genes near super-enhancers.\",\n      \"method\": \"Quantitative proteomics, chemoproteomics, biochemical fractionation, genetic disruption, small-molecule inhibition, ChIP-seq\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — multiple orthogonal methods (proteomics, chemoproteomics, fractionation, ChIP-seq, genetics) in a single rigorous study establishing the mechanistic relationship\",\n      \"pmids\": [\"27294782\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRD4 interacts with the heat shock factor 1 (HSF1) and, under heat stress, is recruited to nuclear stress bodies where it regulates splicing. BRD4 depletion causes increased intron retention and reduced mRNA abundance of affected transcripts during heat stress.\",\n      \"method\": \"RNA-seq, co-immunoprecipitation, immunofluorescence, BRD4 knockdown\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP for interaction, RNA-seq for splicing phenotype, single lab with two orthogonal methods\",\n      \"pmids\": [\"27536004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"BRD4 phosphorylation by CK2 and dephosphorylation by PP2A modulates its chromatin targeting, transcription factor recruitment, and function in cancer progression. Phosphorylation status is also critical for papillomavirus E1/E2-dependent replication and viral gene transcription.\",\n      \"method\": \"Phosphorylation/dephosphorylation assays, functional transcriptional and replication assays, pharmacological modulation of CK2/PP2A\",\n      \"journal\": \"Drug discovery today. Technologies\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical assays with kinase/phosphatase, functional readouts, synthesis of multiple studies from one lab\",\n      \"pmids\": [\"27769352\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRD4 acts as a transcriptional repressor of autophagy and lysosomal function genes via binding to the histone methyltransferase G9a/EHMT2. During starvation, AMPK and SIRT1 displace chromatin-bound BRD4 to instigate autophagy gene activation. The BRD4-NUT fusion oncoprotein also blocks autophagy and lysosome function.\",\n      \"method\": \"BRD4 knockdown, in vitro and in vivo autophagy assays, ChIP, co-immunoprecipitation, AMPK/SIRT1 pathway manipulation\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, in vitro and in vivo KD with defined autophagy phenotype, epistasis through AMPK/SIRT1 signaling cascade, replicated across multiple conditions\",\n      \"pmids\": [\"28525743\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"BRD4 is required for myogenic differentiation, with preferential binding to the Myog promoter coinciding with increased H3K27 acetylation during C2C12 myoblast differentiation, whereas BRD3 downregulation enhances differentiation, establishing distinct and opposing roles for BRD4 and BRD3 in skeletal myogenesis.\",\n      \"method\": \"RNA interference knockdown of individual BET proteins, ChIP for BRD4 at Myog promoter, BET inhibitor treatment, myogenic differentiation assays\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific KD with defined differentiation phenotype plus ChIP showing promoter occupancy, single lab\",\n      \"pmids\": [\"28733670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"BRD4 associates with and regulates the function of pre-replication factor CDC6 and plays an indispensable role in DNA replication checkpoint signaling. BRD4 inhibition causes rapid reduction in CHK1 phosphorylation and aberrant DNA replication re-initiation.\",\n      \"method\": \"Co-immunoprecipitation, BRD4 inhibition with JQ1/AZD5153, CHK1 phosphorylation assays, DNA replication assays, in vivo xenograft models\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP showing BRD4-CDC6 association plus functional DDR assays, single lab with two orthogonal methods\",\n      \"pmids\": [\"29636547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD4 interacts directly with MTHFD1 (a folate pathway enzyme) in the nucleus, recruiting it to specific genomic loci. Inhibition of either BRD4 or MTHFD1 produces similar changes in nuclear metabolite composition and gene expression, establishing a direct link between folate metabolism and BRD4-dependent transcriptional regulation.\",\n      \"method\": \"Genetic and physical interaction screens, nuclear fractionation, ChIP-seq, co-immunoprecipitation, metabolomics\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — complementary genetic and physical interaction screens, nuclear fractionation, ChIP-seq, and Co-IP with functional metabolomics readout in a single study\",\n      \"pmids\": [\"31133746\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD4 functions as an effector of TGF-β signaling in cardiac fibroblasts, undergoing stimulus-dependent genome-wide redistribution and becoming enriched on a subset of enhancers and super-enhancers. Dynamic chromatin targeting of BRD4 is controlled in part by p38 MAPK and drives RNA polymerase II activation and fibrogenic gene expression.\",\n      \"method\": \"RNA-seq, mass spectrometry, ChIP-seq, BRD4 inhibition (JQ1), TGF-β stimulation, primary adult fibroblasts and in vivo mouse model\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (RNA-seq, mass spec, ChIP-seq) in primary cells and in vivo model, defining signal-responsive mechanism\",\n      \"pmids\": [\"31409188\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD4 is required for hematopoietic stem cell expansion and progenitor development in conditional knockout mice. Despite broadly occupying the macrophage genome and participating in super-enhancer formation, BRD4 is not required for macrophage super-enhancers or inflammatory LPS responses, as knockout macrophages form compensatory BRD4-less super-enhancers.\",\n      \"method\": \"Conditional knockout mice (Brd4 KO), ChIP-seq, transcriptome analysis, LPS stimulation\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo conditional KO with ChIP-seq and transcriptomics, establishing context-dependent role with epistasis in hematopoiesis vs. macrophage biology\",\n      \"pmids\": [\"30842097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD4 regulates necroptosis by promoting transcription of MLKL. BRD4, IRF1, P-TEFb, and RNA polymerase II form a transcription complex at the MLKL locus, and BET inhibitors interfere with this complex formation, downregulating MLKL expression and protecting cells from necroptosis.\",\n      \"method\": \"Cell-based small-molecule screen, Co-immunoprecipitation of transcription complex components, MLKL expression analysis, necroptosis assays\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP of BRD4-IRF1-P-TEFb-RNAPII complex plus functional necroptosis phenotype, single lab\",\n      \"pmids\": [\"30644439\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"BRD4 and P300 are sufficient to trigger genome-wide transcriptional competency during zygotic genome activation in zebrafish. Inhibition of histone acetylation blocks genome activation, establishing that P300 and BRD4 regulate this process through histone acetylation.\",\n      \"method\": \"Live imaging of transcription, maternal mRNA translation block, P300/BRD4 ectopic expression, histone acetylation inhibition, zebrafish embryo model\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — live-cell imaging combined with gain-of-function and loss-of-function experiments with defined molecular mechanism (histone acetylation) in an in vivo developmental system\",\n      \"pmids\": [\"31211993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD4 short isoform (BRD4-S) forms nuclear condensates with liquid-like properties that colocalize with BRD4L, MED1, and H3K27ac sites. BRD4-S condensation is mediated by intrinsically disordered regions and bromodomain binding to DNA and acetylated chromatin, and BRD4-S phosphorylation diminishes condensate formation.\",\n      \"method\": \"Live-cell imaging, fluorescence recovery after photobleaching (FRAP), isoform-specific knockdown, ectopic expression, ChIP-seq, CUT&RUN\",\n      \"journal\": \"Nature structural & molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — FRAP for liquid-like properties, isoform-specific KD and OE, ChIP-seq, multiple orthogonal methods establishing phase separation mechanism\",\n      \"pmids\": [\"32203489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD4 phosphorylates MYC at Thr58, leading to MYC ubiquitination and degradation. BRD4 degradation (but not inhibition) results in increased MYC protein levels. MYC inhibits BRD4's histone acetyltransferase (HAT) activity. ERK1 regulates MYC levels both directly and indirectly by inhibiting BRD4 kinase activity.\",\n      \"method\": \"In vitro kinase assay, phospho-specific antibodies, ubiquitination assays, BRD4 degradation vs. inhibition comparison, HAT activity assays\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase and HAT assays with specific mutagenesis, multiple orthogonal methods establishing BRD4 as a kinase that phosphorylates MYC at Thr58\",\n      \"pmids\": [\"32482868\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD4 inhibits CSF1 expression through suppressing HIF1α, thereby reducing macrophage colony-stimulating factor secretion by tumor cells and blocking proliferation of tumor-associated macrophages.\",\n      \"method\": \"BRD4 inhibitor treatment, gene expression analysis, cytokine secretion assays, xenograft and syngeneic tumor models\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological inhibition with defined molecular target (HIF1α) and functional readout in multiple cancer models, single lab\",\n      \"pmids\": [\"32286255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"BRD4 loss of function causes RNA polymerase II pausing on chromatin, leading to accumulation of R-loops (RNA:DNA hybrids) at BRD4 occupancy sites in S-phase cells, resulting in transcription-replication conflicts and DNA damage. The BRD4 C-terminal domain interacting with P-TEFb is required to prevent R-loop formation.\",\n      \"method\": \"BET protein LOF experiments, RNAPII ChIP-seq, R-loop detection (DRIP-seq), DNA damage assays, domain deletion mutants\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal genomic and biochemical methods, domain-deletion defining the CTM as necessary, mechanistically linking BRD4-PTEFb to R-loop suppression\",\n      \"pmids\": [\"32966794\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"The BRD4 long isoform (BRD4-L) is tumor-suppressive while the BRD4 short isoform (BRD4-S) is oncogenic in breast cancer cell proliferation, migration, and mammary tumor formation. BRD4-S and EN1 comodulate the extracellular matrix-associated matrisome network via enhancer regulation.\",\n      \"method\": \"Isoform-specific knockdown, endogenous protein detection, transgene expression, RNA-seq, ChIP-seq, CUT&RUN, mouse tumor models\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — isoform-specific genetic perturbations in vitro and in vivo, integrated multi-omic profiling, defining opposing functional roles of the two isoforms\",\n      \"pmids\": [\"32446320\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ASXL3 directly interacts with BRD4's extra-terminal (ET) domain via a novel BRD4 binding motif (BBM), functioning as an adaptor protein that maintains BRD4 chromatin occupancy at active enhancers. Genetic depletion of ASXL3 reduces genome-wide H3K27ac levels and BRD4-dependent gene expression in SCLC.\",\n      \"method\": \"Size exclusion chromatography, mass spectrometry, western blot, Co-IP, ChIP-seq, RNA-seq, ASXL3 depletion\",\n      \"journal\": \"Genome medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple biochemical methods (SEC, MS, Co-IP) combined with ChIP-seq and RNA-seq, establishing direct protein-protein interaction and chromatin maintenance mechanism\",\n      \"pmids\": [\"32669118\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 interacts with NIPBL (a cohesin agonist) and BRD4 depletion reduces NIPBL chromatin occupancy, suggesting BRD4 stabilizes NIPBL on chromatin. BRD4 depletion compromises genome folding and loop extrusion, and individual amino acid mutations disrupting the BRD4-NIPBL interaction impede neural crest differentiation into smooth muscle.\",\n      \"method\": \"Co-immunoprecipitation, ChIP-seq, chromatin interaction mapping (Hi-C), imaging, point mutation analysis, conditional Brd4 knockout in neural crest, WAPL loss rescue experiment\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, epistasis (WAPL rescue), point mutations, and Hi-C in an in vivo neural crest model, multiple orthogonal methods establishing BRD4-NIPBL interaction in genome folding\",\n      \"pmids\": [\"34611363\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 chromatin-bound and promoter-associated forms have mutually exclusive activities: chromatin-bound BRD4 mediates histone acetyltransferase (HAT) activity for chromatin remodeling, while promoter-associated BRD4 mediates kinase activity for transcription. JNK-mediated phosphorylation at Thr1186 and Thr1212 triggers transient BRD4 release from chromatin, disrupting HAT activity and potentiating kinase activity toward RNA Pol II, PTEFb, and c-Myc.\",\n      \"method\": \"In vitro kinase and HAT activity assays, phospho-specific antibodies, JNK inhibition and stimulation, functional assays (CD8 expression, EMT)\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase and HAT assays combined with phospho-specific mutagenesis and functional readouts, establishing the JNK-BRD4 switch mechanism\",\n      \"pmids\": [\"39454579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 is required for differentiation and maintenance of terminally fated effector CD8 T cells during infection. BRD4 binds diverse regulatory regions critical to effector T cell differentiation and controls transcriptional activity of terminal effector-specific super-enhancers in vivo. Induced deletion of Brd4 impaired terminal effector T cell phenotype maintenance.\",\n      \"method\": \"Small-molecule inhibition, RNAi, induced genetic deletion (Brd4 conditional KO), ChIP-seq, in vivo infection models, tumor microenvironment models\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple complementary loss-of-function approaches (inhibitor, RNAi, genetic deletion) with ChIP-seq, in vivo infection and tumor models\",\n      \"pmids\": [\"34037670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 phosphorylation by CK2 modulates BRD4 dimerization. Two conserved regions, a coiled-coil motif and the BID (Basic-residue enriched Interaction Domain), form the phosphorylation-dependent dimerization domain (PDD). Bivalent inhibitors induce a conformational change within BRD4 dimers in vitro and in cancer cells.\",\n      \"method\": \"Integrative structural biology, biophysical analysis, in vitro CK2 phosphorylation, domain mutagenesis, bivalent inhibitor studies in cells\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — integrative structural biology with domain mutagenesis and in vitro phosphorylation assays, establishing the phosphorylation-dependent dimerization mechanism\",\n      \"pmids\": [\"34754068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4 is required for FXR-mediated regulation of bile acid homeostasis genes (including SHP and CYP7A1). Liver-specific downregulation of BRD4 disrupts bile acid homeostasis. FXR-activated corepressor SMRT decreases NF-κB binding at inflammatory genes in a BRD4-dependent manner.\",\n      \"method\": \"Liver-specific Brd4 knockdown in mice, gene expression analysis, ChIP, Co-immunoprecipitation of FXR-SMRT-BRD4 complexes\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD model combined with ChIP and Co-IP, single lab with two orthogonal methods\",\n      \"pmids\": [\"33290278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD4 promotes DNA double-strand break resection and homologous recombination via interactions with the SWI/SNF chromatin remodeling complex and resection machinery, as established in a cell-free Xenopus egg extract system, independent of gene expression effects.\",\n      \"method\": \"Cell-free Xenopus egg extract reconstitution, biochemical DSB repair assays, BRD4 immunodepletion, SWI/SNF interaction assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — cell-free reconstitution system in Xenopus extracts, biochemical immunodepletion, and protein-protein interaction assays, establishing gene expression-independent DSB repair function\",\n      \"pmids\": [\"35641523\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRMT2 and PRMT4 methylate BRD4 at R179, R181, and R183, and this arginine methylation selectively promotes BRD4 recruitment to acetylated histones/chromatin for transcriptional regulation and DNA repair. DNA damage induces BRD4 arginine methylation, promoting its chromatin binding for DNA repair. BRD4 arginine methylation deficiency suppresses tumor growth.\",\n      \"method\": \"In vitro methylation assays, Co-IP, ChIP-seq, arginine-to-lysine point mutants, DNA damage assays, tumor growth assays\",\n      \"journal\": \"Science advances\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro methylation reconstitution, Co-IP, ChIP-seq, and structure-function analysis with point mutations, multiple orthogonal methods\",\n      \"pmids\": [\"36475791\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRMT1 asymmetrically methylates BRD4 at R179/181/183 (the same sites also targeted by PRMT2/4), and PRMT1-mediated methylation promotes BRD4 phosphorylation. JMJD6 demethylase antagonizes this methylation. BRD4 R179/181/183K mutant cells show reduced ovarian cancer metastasis.\",\n      \"method\": \"In vitro methylation assays, Co-IP, phosphorylation analysis, arginine-to-lysine mutant expression, in vivo and in vitro invasion assays\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro methylation and Co-IP with functional point mutants, but single lab and partially overlapping with PRMT2/4 findings\",\n      \"pmids\": [\"37737256\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"BRD4 bromodomains are dispensable for RNA polymerase II pause release. A minimal, bromodomain-less C-terminal BRD4 fragment containing the P-TEFb-interacting C-terminal motif (CTM) is both necessary and sufficient to mediate Pol II pause release in the absence of full-length BRD4, indicating a distinct bromodomain-independent BRD4-PTEFb population regulates transcription.\",\n      \"method\": \"Rapid protein depletion (degron system), genetic complementation with domain deletion mutants, nascent transcription analysis (PRO-seq), ChIP-seq\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — rapid depletion with domain-deletion complementation and nascent transcription profiling, multiple orthogonal methods establishing the CTM as the functional domain for Pol II pause release\",\n      \"pmids\": [\"37442129\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BRD4 transcriptional condensate formation is regulated by interplay between chromatin binding and self-assembly: BRD4-chromatin interactions control condensate nucleation rate and multivalent acetylated chromatin sites provide a platform for BRD4 clustering below concentrations required for off-chromatin condensation, providing a mechanism for selective condensate formation at acetylated chromatin regions.\",\n      \"method\": \"Live-cell imaging, coarse-grained simulations, BRD4 chromatin-binding mutant analysis, FRAP\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — live-cell experiments with computational modeling, mutant analysis, single study\",\n      \"pmids\": [\"38656803\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"BRD4 plays a role in histone lactylation (H4K8la) in astrocytes. Targeted silencing of BRD4 in astrocytes significantly reduces H4K8la lactylation, aggravating A1 astrocyte polarization after subarachnoid hemorrhage, affecting neural function recovery.\",\n      \"method\": \"BRD4 siRNA silencing in vitro and in vivo, H4K8la western blot and immunofluorescence, astrocyte polarization assays, murine SAH model\",\n      \"journal\": \"Journal of neuroinflammation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo KD with direct histone lactylation readout, single lab, two orthogonal methods\",\n      \"pmids\": [\"39080649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"BRD4/CEBPD relationship: BRD4 (specifically its bromodomain-1) controls CEBPD expression via enhancer regulation. Endogenous BRD4 protein co-immunoprecipitates with CEBPD, and both proteins co-precipitate the Cebpd promoter and enhancer DNA, forming a BRD4/CEBPD/promoter/enhancer complex that mediates TNF-α-induced SMC inflammation via PDGFRα.\",\n      \"method\": \"ChIP-seq, Co-IP, BRD4 gene silencing, bromodomain-1 vs. -2 domain mutants, enhancer deletion, gain- and loss-of-function experiments\",\n      \"journal\": \"Molecular therapy. Methods & clinical development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ChIP-seq, and domain-specific mutants in a single lab study\",\n      \"pmids\": [\"33768129\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BRD4 is a double bromodomain-containing BET family protein that reads acetylated histones and non-histone proteins to regulate transcription elongation via P-TEFb/CDK9 recruitment, with its C-terminal motif (CTM) being necessary and sufficient for Pol II pause release independent of bromodomains; it has intrinsic kinase activity (phosphorylating MYC at Thr58 and RNA Pol II) and histone acetyltransferase activity, with JNK-mediated phosphorylation switching BRD4 between chromatin-bound HAT-active and promoter-associated kinase-active states; BRD4 forms liquid-liquid phase-separated condensates at acetylated super-enhancers, with condensation driven by intrinsically disordered regions and regulated by phosphorylation and chromatin binding; it recruits condensin II to insulate chromatin from DNA damage signaling, promotes homologous recombination via SWI/SNF interactions, prevents R-loop-mediated transcription-replication conflicts, and facilitates genome folding by stabilizing NIPBL/cohesin on chromatin; it is regulated post-translationally by CK2-mediated phosphorylation (inducing dimerization), PRMT1/2/4-mediated arginine methylation at R179/181/183 (promoting chromatin recruitment and DNA repair), and JMJD6-mediated demethylation; BRD4 has two isoforms with opposing functions in cancer (BRD4-S is oncogenic, BRD4-L is tumor-suppressive in breast cancer), and is targeted for proteasomal degradation by cereblon-based PROTACs.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"BRD4 is a chromatin-associated regulator of transcription that reads acetylated histones through its double bromodomains and couples enhancer/super-enhancer activity to RNA polymerase II elongation by recruiting the P-TEFb elongation factor [#1, #4]. Its association with mitotic chromosomes—where it persists while most regulatory factors dissociate—underlies an essential role in the G2/M transition, and it serves as a cellular tether for viral genomes during mitosis [#0, #1]. BRD4 drives transcriptional pause release through a C-terminal motif (CTM) that binds P-TEFb; this bromodomain-less CTM fragment is necessary and sufficient for Pol II pause release, defining a chromatin-reading-independent transcriptional function, and the CTM–P-TEFb axis prevents R-loop accumulation and transcription–replication conflicts [#29, #18]. Beyond reading acetylation, BRD4 possesses intrinsic kinase activity that phosphorylates MYC at Thr58 to trigger its degradation and acts on RNA Pol II, as well as histone acetyltransferase activity; JNK-mediated phosphorylation at Thr1186/Thr1212 switches BRD4 between a chromatin-bound HAT-active state and a promoter-associated kinase-active state [#16, #22]. BRD4 assembles liquid-like nuclear condensates at acetylated super-enhancers, nucleated by intrinsically disordered regions and bromodomain–chromatin contacts and tuned by phosphorylation, providing selective compartmentalization at multivalent acetylated chromatin [#15, #30]. BRD4 is regulated post-translationally by CK2 phosphorylation, which promotes a phosphorylation-dependent dimerization, and by PRMT1/2/4 arginine methylation at R179/181/183, which enhances chromatin recruitment for transcription and DNA repair and is antagonized by JMJD6 [#24, #27, #28]. It supports genome integrity and architecture by recruiting condensin II to insulate chromatin from DNA damage signaling, promoting double-strand-break resection and homologous recombination via SWI/SNF, and stabilizing NIPBL/cohesin to enable loop extrusion and genome folding [#2, #26, #21]. Two isoforms have opposing roles in breast cancer, with BRD4-S oncogenic and BRD4-L tumor-suppressive, and BRD4 can be eliminated by cereblon-based PROTACs that more effectively suppress MYC than bromodomain inhibition alone [#19, #3].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that BRD4 is a chromatin-retained factor with a cell-cycle function, answering whether it acts during mitosis rather than only in interphase transcription.\",\n      \"evidence\": \"Immunofluorescence/live-cell imaging plus microinjection of neutralizing anti-BRD4 antibody and cell cycle analysis in HeLa cells\",\n      \"pmids\": [\"10938129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular partners mediating mitotic chromosome retention not defined\", \"Link to transcriptional function not yet established at this stage\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the core transcriptional mechanism—bromodomain reading of acetylated chromatin and recruitment of P-TEFb/Mediator—and a viral-tethering adaptor role, framing BRD4 as a transcription elongation factor.\",\n      \"evidence\": \"Co-immunoprecipitation, transcriptional reporter assays, and biochemical fractionation (review synthesizing prior experimental work)\",\n      \"pmids\": [\"17329240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Domain dependence of P-TEFb recruitment not dissected\", \"Quantitative contribution to elongation versus initiation unresolved\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Showed BRD4 actively restrains DNA damage signaling via condensin II recruitment, extending its role from transcription to chromatin compaction and the DDR.\",\n      \"evidence\": \"High-content RNAi screen with loss/gain-of-function, chromatin compaction and irradiation survival assays\",\n      \"pmids\": [\"23728299\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Isoform specificity of the effect not fully resolved\", \"Direct condensin II contact interface not mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated that targeted degradation of BRD4 differs functionally from bromodomain inhibition, establishing a degrader strategy and revealing inhibitor-induced protein accumulation.\",\n      \"evidence\": \"PROTAC (ARV-825)-mediated cereblon recruitment, western blot, viability and apoptosis assays across cell lines\",\n      \"pmids\": [\"26051217\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Degron site preferences on BRD4 not defined\", \"In vivo durability of degradation not assessed here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected BRD4 chromatin binding to upstream histone modifications (DOT1L/H3K79me2-driven H4 acetylation) and to heat-stress splicing and CK2/PP2A regulation, broadening its regulatory inputs.\",\n      \"evidence\": \"Quantitative/chemoproteomics, fractionation, ChIP-seq, genetics (DOT1L); Co-IP and RNA-seq (HSF1/splicing); kinase/phosphatase assays (CK2/PP2A)\",\n      \"pmids\": [\"27294782\", \"27536004\", \"27769352\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CK2/PP2A regulation and splicing roles share a common mechanism unclear\", \"Direct vs indirect effects of DOT1L on BRD4 occupancy not fully separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Revealed context-specific and repressive transcriptional roles—silencing autophagy/lysosomal genes via G9a and driving myogenic gene programs—showing BRD4 is not uniformly an activator.\",\n      \"evidence\": \"Knockdown, ChIP, reciprocal Co-IP, AMPK/SIRT1 manipulation (autophagy); BET-protein-specific RNAi and ChIP at Myog (myogenesis)\",\n      \"pmids\": [\"28525743\", \"28733670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Determinants selecting activation versus repression at a given locus unknown\", \"BRD4 vs BRD3 functional divergence mechanism unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked BRD4 to replication-checkpoint control through association with CDC6 and CHK1 signaling, adding a replication-stress arm to its genome-maintenance functions.\",\n      \"evidence\": \"Co-IP, JQ1/AZD5153 inhibition, CHK1 phosphorylation and replication assays, xenografts\",\n      \"pmids\": [\"29636547\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs transcription-mediated effect on the checkpoint not separated\", \"Reciprocal validation of BRD4-CDC6 interaction limited\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined signal-responsive genome-wide redistribution and tissue-specific requirements of BRD4, plus a nuclear metabolic partnership with MTHFD1, establishing it as a context-dependent enhancer effector.\",\n      \"evidence\": \"ChIP-seq/RNA-seq/mass-spec in TGF-β-stimulated fibroblasts; conditional Brd4 KO mice (hematopoiesis/macrophages); interaction screens and metabolomics (MTHFD1); zebrafish ZGA gain/loss-of-function with P300; Co-IP of BRD4-IRF1-P-TEFb-RNAPII at MLKL\",\n      \"pmids\": [\"31409188\", \"30842097\", \"31133746\", \"31211993\", \"30644439\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why some super-enhancers are BRD4-independent (compensatory) is unexplained\", \"Mechanism of MTHFD1 nuclear recruitment to specific loci not defined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established BRD4 as a phase-separating, dual-isoform protein with intrinsic MYC-directed kinase activity and an R-loop-suppressing CTM–P-TEFb function, integrating biophysics, enzymology, and genome stability.\",\n      \"evidence\": \"FRAP/live imaging and isoform-specific KD (condensates, isoform functions); in vitro kinase/HAT and ubiquitination assays (MYC Thr58); DRIP-seq and domain mutants (R-loops); inhibitor/HIF1α/CSF1 tumor models\",\n      \"pmids\": [\"32203489\", \"32446320\", \"32482868\", \"32966794\", \"32286255\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Catalytic identity/structure of the BRD4 kinase module not resolved\", \"How condensate formation mechanistically couples to elongation unclear\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Mapped post-translational and architectural control of BRD4—CK2-driven dimerization, arginine methylation–regulated recruitment, NIPBL/cohesin stabilization for genome folding, and adaptor-mediated chromatin retention—plus differentiation roles.\",\n      \"evidence\": \"Integrative structural biology and CK2 assays (dimerization); in vitro methylation/Co-IP/ChIP-seq with R-to-K mutants (PRMT1/2/4, JMJD6); Co-IP, Hi-C, point mutations and WAPL rescue (NIPBL); SEC/MS/Co-IP (ASXL3); conditional KO and ChIP-seq (CD8 T cells); ChIP/Co-IP (FXR, CEBPD)\",\n      \"pmids\": [\"34754068\", \"36475791\", \"37737256\", \"34611363\", \"32669118\", \"34037670\", \"33290278\", \"33768129\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How dimerization, methylation, and condensation are coordinated is unresolved\", \"Structural basis of the NIPBL and ASXL3 (ET-domain BBM) interactions partially defined\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Resolved that BRD4 promotes HR-directed DSB repair biochemically via SWI/SNF, independent of transcription, and that JNK phosphorylation toggles its HAT versus kinase activities, separating its enzymatic states.\",\n      \"evidence\": \"Cell-free Xenopus extract reconstitution and immunodepletion (HR/SWI/SNF); in vitro kinase/HAT assays with phospho-mutants and JNK modulation (activity switch)\",\n      \"pmids\": [\"35641523\", \"39454579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the kinase/HAT switch operates at endogenous physiological stoichiometry in vivo unclear\", \"Direct SWI/SNF contact interface on BRD4 not mapped\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed bromodomains are dispensable for Pol II pause release, isolating the CTM–P-TEFb module as the necessary and sufficient elongation effector, and refined the chromatin-versus-self-assembly logic of condensate nucleation.\",\n      \"evidence\": \"Degron depletion with domain-deletion complementation and PRO-seq/ChIP-seq (CTM); live imaging, FRAP, chromatin-binding mutants and simulations (condensate nucleation)\",\n      \"pmids\": [\"37442129\", \"38656803\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How the bromodomain-dependent and bromodomain-independent BRD4 pools are partitioned in cells unknown\", \"In vivo relevance of off-chromatin condensation thresholds untested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended BRD4 function to histone lactylation, linking it to H4K8la deposition and astrocyte polarization in injury, suggesting broader histone-acylation reader/effector roles.\",\n      \"evidence\": \"BRD4 siRNA in vitro/in vivo, H4K8la western/immunofluorescence, astrocyte polarization in a murine subarachnoid hemorrhage model\",\n      \"pmids\": [\"39080649\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether BRD4 directly recognizes or enzymatically promotes lactylation not established\", \"Mechanism connecting BRD4 to A1 polarization undefined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural and catalytic basis of BRD4's intrinsic kinase and HAT activities, and how its enzymatic, dimerization, methylation, and phase-separation states are integrated to select genomic targets, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No reported structure of the BRD4 kinase or HAT catalytic module\", \"Interplay among PTMs, dimerization, and condensation in target selection not mechanistically integrated\", \"Determinants of activator versus repressor behavior at individual loci unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0042393\", \"supporting_discovery_ids\": [1, 4, 27]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [1, 7, 29]},\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [16, 22]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [16, 22]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [1, 20, 21]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [15]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 15, 22]},\n      {\"term_id\": \"GO:0000228\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [10, 15]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [1, 4, 29]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 15, 21]},\n      {\"term_id\": \"R-HSA-73894\", \"supporting_discovery_ids\": [2, 26, 27]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 9]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 22]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [8, 14, 21, 23]}\n    ],\n    \"complexes\": [\"P-TEFb elongation complex\", \"Mediator\", \"condensin II\", \"SWI/SNF\"],\n    \"partners\": [\"CDK9\", \"NIPBL\", \"MTHFD1\", \"ASXL3\", \"HSF1\", \"CDC6\", \"IRF1\", \"CEBPD\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}